Threebrooks Therapeutics is a biotech company dedicated to developing innovative treatments for neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. Our lead program, 3BT-1, is a first-in-class small-molecule agonist of the lysosomal ion channel TRPML1. By promoting lysosomal Ca²? efflux, 3BT-1 simultaneously clears amyloid beta, tau aggregates, and damaged mitochondria, offering a novel multi-target therapeutic approach beyond existing antibody-based therapies. The program is currently in lead optimization with a Development Candidate nomination expected in Q2 2026.
In addition to drug discovery, Threebrooks provides world-class translational CRO services, including brain slice patch-clamp electrophysiology, hERG cardiac safety assays, and in vitro/in vivo efficacy testing for CNS disorders. Our capabilities help pharmaceutical and biotech partners generate high-quality preclinical data to accelerate drug development.

Drug development of Alzheimer's Disease using Lysosomal modulator, Nonclinical CRO service for Alzheimer/Parkinson disease